Form 4: Protara Therapeutics Executive Sells Shares
Statement of Changes in Beneficial Ownership
Protara Therapeutics' Chief Commercial Officer, William Conkling, reported a transaction involving the sale of 6,008 shares of common stock.
Summary
- William Conkling, Chief Commercial Officer at Protara Therapeutics, Inc., engaged in a transaction on June 2, 2026.
- The transaction involved the disposition of 6,008 shares of common stock.
- These shares were withheld by the Issuer to cover income tax obligations related to the vesting of Restricted Stock Unit Awards granted on June 2, 2025.
- Following this transaction, Mr. Conkling beneficially owns 69,992 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine tax-related stock withholding by an executive rather than a strategic investment or divestment decision.
Negatives
- The disposition of 6,008 shares represents a reduction in the reporting person's direct beneficial ownership.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to a stock transaction by an executive.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider stock transactions and do not inherently signal company performance, but rather executive compensation and tax management strategies.
Stakeholder Impact
- Shareholders: The transaction does not directly impact the company's operations or financial health, but it is a standard disclosure regarding executive compensation and tax management.
Key Dates
| Date | Description |
|---|---|
| 06/02/2025 | Grant date of Restricted Stock Unit Awards to William Conkling. |
| 06/02/2026 | Date of transaction (withholding of shares for tax obligations) and earliest transaction date reported. |
| 06/03/2026 | Signature date of the Form 4 filing. |
Keywords
Protara Therapeutics, TARA, Form 4, SEC Filing, Stock Transaction, Beneficial Ownership, Restricted Stock Units, William Conkling
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.